Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.

ABSTRACT:

Purpose

Recent data from randomized clinical trials with oncolytic viral therapies and with cancer immunotherapies have finally recapitulated the promise these platforms demonstrated in preclinical models. Perhaps the greatest advance with oncolytic virotherapy has been the appreciation of the importance of activation of the immune response in therapeutic activity. Meanwhile, the understanding that blockade of immune checkpoints (with antibodies that block the binding of PD1 to PDL1 or CTLA4 to B7-2) is critical for an effective antitumor immune response has revitalized the field of immunotherapy. The combination of immune activation using an oncolytic virus and blockade of immune checkpoints is therefore a logical next step.

Experimental design

Here, we explore such combina

SUBMITTER: Rojas JJ 

PROVIDER: S-EPMC4681662 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature